Citigroup’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.36B | Sell |
10,663,404
-1,863,806
| -15% | -$233M | 0.58% | 27 |
|
|
2025
Q4 | $1.53B | Buy |
12,527,210
+1,636,319
| +15% | +$188M | 0.67% | 24 |
|
|
2025
Q3 | $1.09B | Sell |
10,890,891
-1,862,849
| -15% | -$168M | 0.49% | 32 |
|
|
2025
Q2 | $1.06B | Buy |
12,753,740
+2,275,774
| +22% | +$182M | 0.52% | 30 |
|
|
2025
Q1 | $850M | Sell |
10,477,966
-673,629
| -6% | -$60.2M | 0.43% | 33 |
|
|
2024
Q4 | $1B | Buy |
11,151,595
+3,401,781
| +44% | +$330M | 0.6% | 25 |
|
|
2024
Q3 | $766M | Buy |
7,749,814
+492,376
| +7% | +$48.4M | 0.44% | 33 |
|
|
2024
Q2 | $673M | Sell |
7,257,438
-1,564,914
| -18% | -$140M | 0.43% | 40 |
|
|
2024
Q1 | $837M | Buy |
8,822,352
+4,714,266
| +115% | +$437M | 0.55% | 23 |
|
|
2023
Q4 | $367M | Sell |
4,108,086
-1,509,283
| -27% | -$112M | 0.26% | 60 |
|
|
2023
Q3 | $410M | Buy |
5,617,369
+759,221
| +16% | +$60.6M | 0.31% | 48 |
|
|
2023
Q2 | $404M | Sell |
4,858,148
-1,408,226
| -22% | -$118M | 0.27% | 54 |
|
|
2023
Q1 | $478M | Sell |
6,266,374
-1,225,012
| -16% | -$102M | 0.33% | 36 |
|
|
2022
Q4 | $622M | Buy |
7,491,386
+2,570,152
| +52% | +$208M | 0.5% | 24 |
|
|
2022
Q3 | $390M | Sell |
4,921,234
-129,263
| -3% | -$10.9M | 0.28% | 54 |
|
|
2022
Q2 | $375M | Buy |
5,050,497
+1,011,470
| +25% | +$75.9M | 0.28% | 50 |
|
|
2022
Q1 | $363M | Buy |
4,039,027
+398,170
| +11% | +$36.8M | 0.22% | 67 |
|
|
2021
Q4 | $408M | Buy |
3,640,857
+997,524
| +38% | +$120M | 0.22% | 71 |
|
|
2021
Q3 | $332M | Sell |
2,643,333
-3,070,303
| -54% | -$395M | 0.2% | 80 |
|
|
2021
Q2 | $774M | Sell |
5,713,636
-581,322
| -9% | -$76.4M | 0.47% | 33 |
|
|
2021
Q1 | $854M | Buy |
6,294,958
+271,735
| +5% | +$40.7M | 0.55% | 21 |
|
|
2020
Q4 | $848M | Sell |
6,023,223
-1,940,587
| -24% | -$249M | 0.5% | 26 |
|
|
2020
Q3 | $887M | Buy |
7,963,810
+30,234
| +0.4% | +$3.39M | 0.58% | 23 |
|
|
2020
Q2 | $888M | Sell |
7,933,576
-2,539,417
| -24% | -$250M | 0.69% | 19 |
|
|
2020
Q1 | $811M | Buy |
10,472,993
+2,256,262
| +27% | +$200M | 0.73% | 17 |
|
|
2019
Q4 | $781M | Sell |
8,216,731
-1,942,137
| -19% | -$168M | 0.57% | 19 |
|
|
2019
Q3 | $775M | Buy |
10,158,868
+1,949,248
| +24% | +$162M | 0.61% | 12 |
|
|
2019
Q2 | $720M | Sell |
8,209,620
-242,126
| -3% | -$20.7M | 0.58% | 13 |
|
|
2019
Q1 | $765M | Buy |
8,451,746
+500,027
| +6% | +$42.5M | 0.74% | 10 |
|
|
2018
Q4 | $571M | Buy |
7,951,719
+2,301,333
| +41% | +$185M | 0.58% | 18 |
|
|
2018
Q3 | $542M | Sell |
5,650,386
-17,823
| -0.3% | -$1.73M | 0.48% | 24 |
|
|
2018
Q2 | $540M | Sell |
5,668,209
-820,024
| -13% | -$75.4M | 0.5% | 21 |
|
|
2018
Q1 | $570M | Buy |
6,488,233
+186,469
| +3% | +$17M | 0.47% | 25 |
|
|
2017
Q4 | $535M | Buy |
6,301,764
+1,395,984
| +28% | +$117M | 0.43% | 25 |
|
|
2017
Q3 | $425M | Sell |
4,905,780
-1,838,302
| -27% | -$147M | 0.35% | 28 |
|
|
2017
Q2 | $521M | Buy |
6,744,082
+1,910,329
| +40% | +$135M | 0.47% | 19 |
|
|
2017
Q1 | $335M | Buy |
4,833,753
+1,015,676
| +27% | +$68.2M | 0.3% | 39 |
|
|
2016
Q4 | $226M | Sell |
3,818,077
-4,458,311
| -54% | -$275M | 0.2% | 65 |
|
|
2016
Q3 | $549M | Buy |
8,276,388
+2,504,448
| +43% | +$155M | 0.51% | 16 |
|
|
2016
Q2 | $312M | Buy |
5,771,940
+2,724,343
| +89% | +$149M | 0.32% | 38 |
|
|
2016
Q1 | $157M | Buy |
3,047,597
+264,232
| +9% | +$13.7M | 0.18% | 81 |
|
|
2015
Q4 | $195M | Sell |
2,783,365
-67,495
| -2% | -$4.6M | 0.19% | 82 |
|
|
2015
Q3 | $177M | Sell |
2,850,860
-927,499
| -25% | -$73.1M | 0.17% | 87 |
|
|
2015
Q2 | $318M | Buy |
3,778,359
+893,637
| +31% | +$69.5M | 0.28% | 36 |
|
|
2015
Q1 | $217M | Buy |
2,884,722
+1,510,386
| +110% | +$106M | 0.21% | 67 |
|
|
2014
Q4 | $85.5M | Buy |
1,374,336
+288,126
| +27% | +$16.4M | 0.08% | 253 |
|
|
2014
Q3 | $56.5M | Sell |
1,086,210
-589,530
| -35% | -$30.1M | 0.05% | 345 |
|
|
2014
Q2 | $86M | Buy |
1,675,740
+62,418
| +4% | +$2.81M | 0.08% | 224 |
|
|
2014
Q1 | $76.6M | Sell |
1,613,322
-57,153
| -3% | -$2.93M | 0.08% | 206 |
|
|
2013
Q4 | $72.5M | Buy |
1,670,475
+732,495
| +78% | +$30.3M | 0.07% | 274 |
|
|
2013
Q3 | $40.4M | Sell |
937,980
-1,639,707
| -64% | -$66.4M | 0.04% | 434 |
|
|
2013
Q2 | $89.6M | Buy |
+2,577,687
| New | +$90.6M | 0.09% | 172 |
|
Other funds holding XBI
JFG
Citigroup's XBI Position: Q1 2026 in Review
Citigroup reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, selling an estimated $233M and leaving 10,663,404 shares worth $1.36B. The position accounts for 0.58% of the portfolio, ranked #27.
Citigroup first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.53B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Citigroup held 10,663,404 shares of State Street SPDR S&P Biotech ETF worth $1.36B as of Q1 2026.
- Citigroup sold 1,863,806 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $233M.
- State Street SPDR S&P Biotech ETF made up 0.58% of Citigroup's portfolio in Q1 2026, its #27 holding.
- Citigroup first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- Citigroup's State Street SPDR S&P Biotech ETF position peaked at $1.53B in Q4 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.